Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Evolus, Inc. on behalf of Evolus stockholders. Its investigation concerns whether Evolus has violated the federal securities laws and/or engaged in other unlawful business practices.
Evolus is a California-based medical aesthetics company. The company and its South Korean partner, Daewoong Pharmaceutical Co., developed Jeuveau, a competitor to Allergan’s Botox. Jeuveau has recently become a strong, more affordable competitor of Botox.
Read more at GlobeNewswire >>